Table 1.

Characteristics of the included studies.

Study	Year	Design	Number of patients		Treatment		Stage	Outcomes
			Trial	Control	Trial	Control
Reck M, et al. (17)	2010	Multicenter, randomized, double-blind phase III study	696	347	CG+bevacizumab 7.5 mg/kg (arm1) or 15 mg/kg (arm2)	CG	Advanced or recurrent non-squamous NSCLC	OS
Reck M, et al. (14)	2009	Multicenter, randomized, double-blind phase III study	696	347	CG+bevacizumab 7.5 mg/kg (arm1) or 15 mg/kg (arm2)	CG	Advanced or recurrent non-squamous NSCLC	PFS, ORR, AEs
Zhou C, et al. (10)	2015	Multicenter, randomized, double-blind phase III study	138	138	CP+bevacizumab 15 mg/kg	CP	Advanced or recurrent non-squamous NSCLC	OS, PFS, ORR, AEs
Niho S, et al. (13)	2012	Multicenter, randomized, open-label, phase II study	121	59	CP+bevacizumab 15 mg/kg	CP	Advanced or recurrent non-squamous NSCLC	OS, PFS, ORR, AEs
Sandler A, et al. (8)	2006	Multicenter, randomized, open-label, phase III study	427	440	CP+bevacizumab 15 mg/kg	CP	Advanced or recurrent non-squamous NSCLC	OS, PFS, ORR, AEs
Johnson D.H, et al. (25)	2004	Multicenter, randomized, open-label, phase II study	67	32	CP+bevacizumab 7.5 mg/kg (arm1) or 15 mg/kg (arm2)	CP	Advanced or recurrent NSCLC	OS, PFS, ORR, AEs

CG, cisplatin-gemcitabine; CP, carboplatin-paclitaxel; OS, overall survival; PFS, progression-free survival; ORR, objective response rate; AEs, adverse events; NSCLC, non-small cell lung cancer.